Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a prostate cancer poster session. Dr. Ida Sonni presented a study evaluating the diagnostic performance of 18 ...

After re-staging patients, ideally with PSMA-PET, and performing a biopsy to confirm the recurrence and stratify them into risk categories, it is time to discuss local salvage treatment. Options ...

The primary study objective was to evaluate the prognostic value of post-therapeutic SPECT by RECIP 1.0 for overall survival.

In Meraouna et al.'s study, the failure-free survival rate was 66% at 3 years of follow-up. Regarding treatment-related morbidities, 12.3% of patients experienced grade 3 genitourinary (GU) toxicity, ...

Patients with mHSPC benefited from darolutamide + ADT + docetaxel irrespective of age (<75 years and ≥75 years), with consistent improvements in overall survival, time to mCRPC, and time to initiation ...

In the post-op SAKK 09/10 trial, only patients in the higher PORTOS score group benefited from radiation therapy dose escalation (clinical progression free survival HR 0.19, 95% CI 0.05-0.70; p = 0.01 ...

The primary endpoint is objective response rate, with progression-free survival a key secondary endpoint. The study includes a pre-registration step for arm determination by the molecular tumor board.

Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to prostate cancer poster session. Dr. Zachary Klaassen presented the results of a population-based analysis evaluating ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Fred Saad discussing a subgroup analysis of the phase 3 ARANOTE trial assessing darolutamide + ADT in patients with ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

Upper tract urothelial carcinoma (UTUC) is an aggressive disease that is challenging to biopsy and diagnose, frequently yielding nondiagnostic cytology and tissue specimens. Therefore, UTUC is often ...

We evaluated the potential diagnostic utility of PET with the cellular proliferation biomarker, 2'-deoxyl-2'-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU), as an adjunct to ...